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Abstract: The incidence of both type 2 diabetes mellitus (T2DM) and multiple cancer types are rapidly 
increasing worldwide. Several studies documented that T2DM is closely associated with an increased 
incidence of cancer. However, while some methodological considerations preclude a definitive association 
between T2DM and the risk of certain cancers, the relationship between T2DM and increased risk of 
incident hepatocellular carcinoma (HCC) remains significant even after adjustment for detection bias and 
reverse causation, indicating that such association is clinically reliable and robust. In addition, a number of 
observational studies also showed that T2DM is associated with higher mortality among persons with HCC. 
Some recent meta-analyses suggested that treatment with metformin may be associated with a lower risk of 
HCC, and may also beneficially influence HCC prognosis, whereas treatment with sulphonylureas or insulin 
seems to be related to a higher HCC risk. The underlying biological mechanisms linking T2DM and HCC 
are complex and difficult to elucidate, but the existence of close inter-connections among T2DM, obesity 
and nonalcoholic fatty liver disease (NAFLD) induces hepatic/systemic insulin resistance and causes the 
release of multiple pro-inflammatory cytokines, vasoactive factors and pro-oxidant molecules, which are all 
potentially implicated in the development and progression of HCC. In this clinical review, we discuss the 
epidemiological evidence linking T2DM to the risk of HCC. Moreover, we also briefly discuss the putative 
underlying mechanisms linking T2DM, NAFLD and HCC, and the potential effect of certain hypoglycemic 
agents on the risk of developing HCC. 
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Introduction
The French surgeon Theodore Tuffier was probably the 
first one to hypothesize the existence of a relationship 
of type 2 diabetes mellitus (T2DM) with cancer risk in 
the second half of nineteenth century (1,2). He observed 
that patients with established T2DM exhibited a greater 
risk of certain cancers than those without diabetes (1,2). 
Consequently, he formulated the following key questions: 
(I) could diabetes affect the incidence of cancer? (II) could 
diabetes influence the natural history of cancer? and (III) 
could cancer affect the natural history of diabetes? (1,2). 
To date, seeing that the incidence of both T2DM 
and cancer are rapidly increasing worldwide, the above-
mentioned questions remain of considerable clinical 
importance for investigating the epidemiological and 
pathophysiological associations between T2DM and cancer 
risk (3-6). These questions are particularly important for the 
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relationship between T2DM and the risk of hepatocellular 
carcinoma (HCC), because the incidence of this cancer 
has rapidly increased over the last decade and it represents 
now the third cause of cancer-related mortality worldwide 
(7,8). Moreover, there is now clear evidence that T2DM 
and HCC are closely linked, owing to their association with 
obesity, impaired insulin sensitivity and nonalcoholic fatty 
liver disease (NAFLD) (9-14). In particular, the increasing 
incidence of HCC is, in large part, attributable to the rising 
prevalence and incidence of NAFLD worldwide. Indeed, 
the prognostic impact of NAFLD per se on HCC risk is 
currently taking increasingly greater clinical importance. 
NAFLD encompasses a spectrum of progressive hepatic 
disease (ranging from pure steatosis to steatohepatitis 
[NASH] and cirrhosis) that is often observed in patients 
with T2DM (occurring in up to 70% of these patients) 
(15-19). Over the last decade, strong evidence demonstrated 
that patients with T2DM are more likely to develop 
the more severe histologic forms of NAFLD, including 
cirrhosis and HCC (15-19). 
Given the sharp rise in the global incidence of T2DM, 
NAFLD and HCC, it is therefore unsurprising that in 
clinical practice, diabetologists often have to manage 
diabetes in patients who are being treated for HCC and 
oncologists/gastroenterologists are increasingly required to 
plan cancer treatment for patients with pre-existing diabetes. 
It is hence very important that diabetologists, oncologists, 
gastroenterologists but also general practitioners are aware 
of the strong relationship between T2DM and the risk of 
incident HCC. 
In this clinical review, we will examine the evidence 
for a link between T2DM, NAFLD and HCC from an 
epidemiological and a pathophysiological perspective. 
Moreover, we will also briefly discuss the potential effect of 
certain hypoglycemic agents on HCC risk. 
 
Epidemiological studies linking T2DM to  
cancer risk
Currently, the estimated global prevalence of T2DM is 
approximately 9% worldwide, with a worrying tendency to 
increase sharply in the next years (3,4,20,21). In parallel, 
the total number of deaths attributed to cancer is estimated 
to rise over time, mainly in developing countries (5). For 
instance, it was calculated that there were approximately 
8 million cancer-related deaths worldwide in 2012 (5). 
There is also strong evidence indicating that cancer risk 
and mortality are progressively increasing with the rise of 
T2DM incidence (22-24). For example, on the basis of a 
pooled analysis including 97 prospective cohort studies 
with a total of nearly 800,000 individuals, the Emerging 
Risk Factors Collaboration group investigators showed that 
individuals with established diabetes showed a remarkably 
greater risk of mortality from cancer than those without 
diabetes (25). Interestingly, the observed relationships 
between the presence of diabetes and the risk of site-
specific cancer deaths were strongest for the risk of liver and 
pancreatic cancers, intermediate for ovarian and colorectal 
cancers, and lowest for lung and breast cancers (25). Death 
from site-specific cancers was also examined in a cohort 
of nearly 7,200 T2DM patients from Verona (Italy) over 
a 10-year follow-up by reviewing death certificates (26). 
The authors found that mortality rates from site-specific 
cancers were significantly higher in T2DM patients than 
in the general population (26). In particular, increased 
risk of death from liver cancer [standard mortality ratio 
(SMR) =1.86, 95% confidence interval (CI): 1.44–2.38] was 
observed in both sexes. In addition, women with diabetes 
also showed higher risk of death from both pancreatic (SMR 
=1.78, 95% CI: 1.13–2.67) and breast cancers (SMR =1.40, 
95% CI: 1.06–1.81). Other investigators subsequently 
reported similar findings in other countries (27-30). On the 
basis of all these observations, a 2010 consensus statement 
of experts assembled jointly by the American Diabetes 
Association (ADA) and the American Cancer Society (ACS) 
concluded that the incidence rates of liver, pancreatic, 
colorectal, breast, endometrial and bladder cancers were 
increased among individuals with T2DM (31). However, 
it is important to note that while some methodological 
considerations preclude a definitive association between 
T2DM and risk of some cancers, the increased HCC risk 
observed in patients with T2DM remains statistically 
significant even after adjustment for detection bias and 
reverse causation, so indicating that such association is 
clinically reliable and robust (1,26,27,32,33). 
Epidemiological studies linking T2DM to HCC risk
HCC represents the commonest form of primary liver 
cancer (5,6). The worldwide number of incident cases of 
HCC has been estimated to be approximately 600,000 in 
2002, 80% of which were recorded in developing countries. 
Table S1 summarizes the principal observational studies 
and meta-analyses examining the relationship between pre-
existing T2DM and the risk of HCC. An early description 
of the existence of an association between T2DM and HCC 
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has been reported approximately 30 years ago (34). In 1986, 
in a case-control study involving 105 HCC patients and 
105 persons with either colorectal cancer or femoral bone 
fractures who were matched by age and sex, Lawson et al. 
firstly documented that there was an approximately four-
fold risk of prevalent T2DM among patients with HCC 
compared with those with colorectal cancer or femoral bone 
fractures, irrespective of chronic viral hepatitis, alcoholic 
cirrhosis and hemochromatosis (34). Subsequently, in a 
systematic analysis based on 242 cases of primary liver 
cancers and 1,169 controls recorded between 1984 and 
1989, La Vecchia et al. found that patients with T2DM had 
an approximately 2.5-fold increased risk of developing liver 
cancers (mainly owing to HCC), independent of metabolic 
factors and other potential confounding variables (35). 
Notably, such increased risk of HCC was also observed 
in patients with a diagnosis of T2DM that occurred 5 
or more years before the diagnosis of HCC (35). After 
these pioneering reports, several other case-control and 
prospective studies as well as some meta-analyses have 
been conducted, all confirming the existence of a strong 
relationship between T2DM and HCC risk, irrespective 
of several potential confounders, including overweight/
obesity, excessive alcohol consumption and chronic viral 
hepatitis (36-39). For example, in a large meta-analysis 
involving approximately 3 million people, El-Serag et al. 
showed that among 13 case-control studies, pre-existing 
diabetes was associated with risk of prevalent HCC in 
9 studies (odds ratio 2.50; 95% CI: 1.8–3.5). Among 
13 cohort studies, diabetes was associated with risk of 
incident HCC in 7 studies (hazard risk 2.50; 95% CI: 
1.9–3.2). The findings were consistent in different 
populations, different geographic locations, and a variety of 
control groups. The relationship between diabetes and HCC 
risk remained statistically significant after adjusting for 
alcohol use or chronic viral hepatitis in the 10 studies that 
examined these risk factors (40). In another meta-analysis 
published 6 years later, involving 49 observational studies 
(32 cohort studies and 17 case-control studies), Wang et al. 
confirmed that pre-existing T2DM was strongly associated 
with increased HCC prevalence and mortality, independent 
of several confounding factors and metabolic variables (41). 
In 2013, in a large cohort study of 363,426 non-diabetic 
individuals and 8,588 T2DM patients without any cancer 
or metastasis at baseline, Schlesinger et al. reported that 
T2DM was associated with an increased incidence of both 
HCC and bile tract cancer over a follow-up of 8 years, 
independent of age, sex, body mass index (BMI), waist-to-
height ratio, center, education level, smoking and alcohol 
consumption (42). In a community-based cohort study of 
63,257 Chinese individuals followed-up for 10 years, Koh 
et al. showed that T2DM was associated with increased 
incidence of non-viral HCC, irrespective of age, sex, BMI, 
recruitment year, dialect group, education level, smoking 
and consumption of alcohol, coffee or tea (43). In 2015, in 
an Italian hospital-based case-control study of 224 HCC 
patients and 389 control subjects, Miele et al. found that the 
risk of HCC was significantly increased among patients with 
T2DM, especially among those with a longer duration of 
disease (44). Recently, in a meta-analysis of 9 studies 
(7 cohort studies and 2 case-control studies), Dyal 
et al. examined the inter-relationships of T2DM, obesity 
and hepatic steatosis with incidence rates of HCC in 
patients with chronic hepatitis C virus (HCV) (45). These 
authors documented that T2DM was closely associated 
with increased risk of HCC in this patient population, 
independent of age, sex, obesity, hypertension, smoking, 
alcohol intake, serum liver enzymes, albumin, lipids, platelet 
count, and presence of cirrhosis and hepatic steatosis (45). 
Notably, the presence of obesity and hepatic steatosis (along 
with T2DM) were also found to be independent predictors 
of incident HCC (45). These findings are clinically relevant, 
because they would suggest a potential synergistic, additive 
interaction between T2DM and other major metabolic risk 
factor for HCC. 
Epidemiological studies linking NAFLD to HCC risk
Over the last years, it has become increasing clear that 
NAFLD is strongly associated with increased risk of incident 
HCC. For instance, in a US population-based cohort study 
of 4,406 HCC cases followed-up for approximately 6 years, 
Sanyal et al. reported that the most common risk factor for 
HCC was NAFLD, followed by T2DM and HCV chronic 
infection (46). Almost identical findings were found in a 
smaller study showing that NAFLD was the most common 
etiology for HCC, thus outstripping chronic viral hepatitis 
and alcoholic liver disease (47). 
Although there is now epidemiologic evidence to indicate 
a close relationship between NAFLD or NASH and the 
HCC risk, this risk appears to be particularly elevated in 
patients with cirrhosis, which is a well-established risk 
factor for HCC (11,12,48). In a national cohort of 1,500 
patients who developed HCC from 2005 through 2010 
from Veterans Administration hospitals, Mittal et al. showed 
that NAFLD was the third most common risk factor 
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for HCC, and that more than half of these patients had 
cirrhosis (49). In a large meta-analysis of 17 cohort studies, 
18 case-control or cross-sectional studies and 26 case-series, 
White et al. reported that the cohorts of NAFLD or NASH 
patients with few or no cases of cirrhosis showed a minimal 
risk of HCC (HCC mortality of 0–3% for study follow-ups 
up to 20 years). The cohorts of patients with NASH and 
cirrhosis had a substantially greater risk (HCC incidence 
ranging from 2.4% over 7 years to 12.8% over 3 years). 
However, the HCC risk was lower in the cohorts of patients 
with NASH-cirrhosis than for cohorts with HCV-related 
cirrhosis (50). Similarly, in a prospective study enrolling 
315 patients with HCV-cirrhosis and 195 patients with 
NASH-cirrhosis who were followed-up for approximately 
4 years, Ascha et al. found that the yearly cumulative HCC 
incidence among patients with NASH-cirrhosis was 2.6% 
compared to 4.0% among those with HCV-cirrhosis (51). 
It is important to remark that in all the above-mentioned 
studies other major risk factors for development of HCC 
were older age, excessive alcohol consumption, pre-existing 
T2DM and presence of hepatic iron accumulation. Notably, 
some studies also suggested that the overall survival in 
cirrhotic NAFLD patients with HCC was significantly 
shorter compared with that observed in patients with 
HCC secondary to HCV cirrhosis (48,52,53). A plausible 
explanation for this intriguing finding is that cirrhotic 
NAFLD patients with HCC were older, and more likely to 
have larger tumor diameters and less surveillance compared 
to patients with HCC secondary to HCV cirrhosis (48). 
Conversely, the overall survival of patients with NAFLD-
related HCC and neoplastic lesions eligible for curative 
treatment appeared to be superimposable to that observed 
in patients with HCC secondary to HCV cirrhosis (48).
Interestingly, however, in the last years the concept that 
HCC develops only in patients with cirrhotic NAFLD has 
been challenged, as HCC has been increasingly recognized 
in non-cirrhotic patients with NASH (11,48,54-57). For 
example, in a small cross-sectional study of 54 patients 
with HCC resulting by NAFLD, Leung et al. reported 
that approximately 15% of them were not cirrhotic, and 
that non-cirrhotic NAFLD patients had a significantly 
larger mean tumor diameter at diagnosis compared to 
those with cirrhosis (58). In another small study of 36 
patients without cirrhosis and 47 NAFLD-HCC patients 
with cirrhosis, Mohamad et al. reported that patients with 
NAFLD-HCC in the absence of cirrhosis had larger 
tumor diameters at diagnosis, higher tumor recurrence 
rates and worse survival outcomes compared to NAFLD-
HCC patients with cirrhosis (59). To further increase the 
complexity of this problem, some cases of HCC in patients 
with imaging-diagnosed NAFLD (hepatic steatosis) have 
been also recently described. In a Japanese study involving 
6,508 individuals with ultrasound-diagnosed NAFLD 
and followed for a median of nearly 6 years, Kawamura 
et al. found that the cumulative rates of HCC were 0.02% 
after 4 years, 0.20% after 8 years, and 0.51% after 12 years, 
respectively (60). These authors also observed that 
patients with advanced NAFLD fibrosis, as detected by 
aspartate aminotransferase (AST) to platelet ratio index 
(i.e., a non-invasive clinical score for advanced fibrosis), 
had an approximately 25-fold increased incidence of 
HCC compared with those without advanced NAFLD 
fibrosis (60). 
Given that NAFLD is considered to be the “hepatic 
manifestation” of metabolic syndrome, it is unsurprising 
that several epidemiological studies also reported a strong 
association between other metabolic syndrome features, 
such as overweight or obesity, and the risk of developing 
HCC. Over the last decade, some large meta-analyses 
documented that individuals with overweight or obesity had 
a 50% to 85% increased risk of incident HCC compared 
with non-obese individuals (61-63). Similarly, in a large 
follow-up study, including nearly 360,000 individuals from 
the Prospective Investigation into Cancer and Nutrition 
Study, Schlesinger et al. reported a strong and positive 
association between abdominal obesity and HCC incidence 
over a mean follow-up period of 8.6 years (64). 
Putative biological mechanisms linking T2DM 
and NAFLD with HCC risk
The exact pathophysiological mechanisms linking T2DM, 
NAFLD and HCC are not completely understood. 
However, although the pathophysiology underpinning 
these associations are not entirely clear, understanding 
of HCC pathophysiology in this context has improved in 
recent years. 
Figure 1  schematically summarizes the putative 
pathophysiological mechanisms that might link T2DM, 
NAFLD and HCC. 
It is well known that T2DM and NAFLD are strongly 
associated with increased hepatic/peripheral insulin 
resistance, lipotoxicity, increased oxidative stress and 
chronic low-grade inflammatory state. For instance, when 
insulin resistance and lipotoxicity develop, there is an 
increased release of multiple pro-inflammatory cytokines 
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(e.g., C-reactive protein, interleukin-1, interleukin-6, tumor 
necrosis factor-alpha, tumor growth factor-beta), vasoactive 
factors and pro-oxidant molecules into bloodstream 
(13,14,19,65). Several studies suggest that all these factors 
may contribute to the development of HCC by promoting 
hepatic cellular growth/proliferation and by inhibiting 
cellular apoptosis (65-71). In addition, in the presence of 
insulin resistance, insulin concentrations rise in blood, so 
resulting in increased insulin-like growth factor-1 (IGF-1) 
production, i.e., a well-known hormone capable to stimulate 
hepatic cellular growth/proliferation and inhibit cellular 
apoptosis within the liver. Hyperinsulinemia also stimulates 
insulin receptor substrate-1 (IRS-1), which plays a key role 
in the activation of some intracellular cytokine signalling 
pathways implicated in hepatic carcinogenesis (65,72). 
Both T2DM and NAFLD are associated with increased 
oxidative stress and release of reactive oxygen species 
(ROS) (64,70,72). Experimental studies reported that when 
hepatocytes are steatotic, they are able to produce ROS 
(65,73-76). It is known that increased ROS and oxidative 
stress may promote the development of many types of 
cancer, including HCC (65,71,73-76). Indeed, ROS can 
lead to cytotoxicity, DNA damage as well as activation and 
suppression of multiple genes that are potentially implicated 
in the cellular proliferation and growth (e.g., c-Jun amino 
terminal kinase 1 [c-JNK], p53, D-cycline, c-Fos, c-RAS, 
and c-Myc), thus further promoting hepatic carcinogenesis 
(65,71,73-76). In addition, increased production of ROS 
can be due to mitochondrial dysfunction (i.e., structural 
mitochondrial lesions, decreased activity of the respiratory 
Type 2 diabetes mellitus
Hepat ic/per ipheral 
insulin resistance
↑  Ce l l  g rowth 
and proliferation
↓ Cellular apoptosis
NAFLD
Hepatocellular 
carcinoma
↑ Angiogenesis ↑ DNA damage
↑Insulin growth 
factor-1
↑Pro-inflammatory state 
and oxidative stress
Intestinal dysbiosis
Figure 1 Putative biological mechanisms linking type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD) to the development 
and progression of hepatocellular carcinoma. The biological mechanisms underlying the association between type 2 diabetes, NAFLD and 
hepatocellular carcinoma are complex and not entirely understood. Both type 2 diabetes and NAFLD are strongly associated with abdominal 
obesity, hepatic/peripheral insulin resistance, low-grade chronic inflammation and increased oxidative stress that may contribute to the 
development and progression of hepatocellular carcinoma, promoting increased cellular growth and proliferation, inhibition of cellular 
apoptosis, increased angiogenesis and DNA damage. Insulin resistance and coexistent chronic hyperinsulinemia lead to increased production 
of insulin-like growth factor 1 (IGF-1), which further promotes hepatic cellular growth/proliferation and inhibits cellular apoptosis within 
the liver. In addition, chronic hyperinsulinemia also activates insulin receptor substrate-1 (IRS-1), which plays a key role in the regulation of 
multiple cytokine pathways potentially implicated in the pathophysiology of hepatocellular carcinoma. Evidence also suggests that insulin 
resistance alters gut microbiota (dysbiosis) and increases circulating levels of free fatty acids, which promote hepatic steatosis (NAFLD); 
both of these pathologic conditions play a part in the development and progression of hepatocellular carcinoma. In particular, clear 
evidence indicates that NAFLD, especially in its necro-inflammatory form, exacerbates hepatic/peripheral insulin resistance and causes the 
intrahepatic release of multiple hepatokines and mediators that increase the risk of hepatic carcinogenesis.
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chain enzymes and abnormal mitochondrial beta-oxidation) 
(65,71,73-76). Interestingly, many experimental studies 
reported that T2DM and NAFLD are associated with the 
presence of mitochondrial dysfunction, thus resulting in 
increased ROS production (65,71,73-76). For an updated 
review on the molecular mechanisms of NAFLD-induced 
hepatocarcinogenesis the interested readers are referred to 
Zoller et al. (14).
Recently, accumulating evidence also suggests that gut 
microbiota alterations might play a part in the pathogenesis 
of T2DM, obesity and NAFLD (77-80). To note, there is 
now some evidence suggesting that altered gut microbiota 
may be also implicated in hepatic carcinogenesis (77-80). 
The putative pathophysiological processes that link altered 
gut microbiota and HCC development are complex, but 
they might include abnormalities in Toll Like Receptors 
(TLRs), increased levels of gut bacterial metabolites, 
increased levels of secondary bile acids with subsequent 
development of intestinal dysbiosis (77-80). With regard 
to intestinal dysbiosis, for example, in a recent case-control 
study including 150 HCC patients (105 with early HCC and 
45 with advanced HCC) and 131 control individuals, Ren 
et al. reported that altered gut microbiota (characterized by 
decreases in Bacteroidetes and increases in Proteobacteria and 
Fusobacteria) was associated with more advanced HCC (81). 
It is plausible to assume that alterations in gut microbiota 
may promote the increased production of multiple fibrotic, 
inflammatory and cancer growth mediators by the hepatic 
stellate cells (77-80). 
To date, the advent of next-generation sequencing 
and other “omics” technologies strongly implemented 
our knowledge(s) about the pathophysiology of HCC 
(65,71,82-89). For example, several studies reported 
recurrent mutations in the cell cycle regulator TP53 and 
CDKN2A, in the gene encoding for albumin, and also in 
the genes of the β-catenin/WNT signaling pathway (i.e., 
CTNNB1 and AXIN1) (65,71,82-89). Using the technique 
of comparative genomic hybridization, other experimental 
reports documented that patients with NASH have a 
greater level of genomic instability compared to those 
without NASH (65,71,82-89). Interestingly, it has been 
recently reported that some epigenetic alterations might 
be also important for HCC development (65,71,82-89). 
For example, the hypermethylation of the E-cadherin-1 
(CDH-1) gene has been related to increased incidence 
of NAFLD-related HCC (65,71,82-89). Accumulating 
evidence also suggests the importance of genetic variation in 
the patatin like phospholipase domain-containing protein-3 
(PNPLA3) gene (65,71,82-89). This gene encodes for a 
protein (named adiponutrin) located in intra-hepatic lipid 
droplets, which is capable to promote hepatic lipogenesis 
and lipolysis (65,71,82-89). The genetic variations of 
PNPLA3 gene have been found to be closely associated with 
increased risk of NAFLD progression, especially with risk 
of hepatic fibrosis (65,71,82-89). It has subsequently been 
shown that carriers of PNPLA3 genetic polymorphism 
encoding for the I148M variant allele are also at higher 
risk of HCC (65,71,82-89). Therefore, genotyping of the 
PNPLA3 I148M polymorphism will reveal mechanisms 
implicated in hepatic fibrogenesis and carcinogenesis and 
will possibly inform clinical practice in the future (i.e., 
contributing to identify those to whom HCC surveillance 
may be targeted). 
Epidemiological studies linking the use of certain 
glucose-lowering medications to HCC risk 
Currently, there is increasing evidence to suggest that 
certain glucose-lowering medications may have a modifying 
effect on incidence rates of HCC. In 2005, Evans et al. 
conducted a pilot study suggesting that metformin use may 
be associated with a lower risk of cancer among individuals 
with known T2DM (90). After this pioneering study, 
other larger studies have been performed. For example, 
in a population-based cohort of 10,309 T2DM patients 
followed-up for nearly 5 years, Bowker et al. reported that 
cancer mortality significantly differed among the various 
treatments for diabetes at baseline: 3.5% for metformin 
users, 4.9% for sulphonylurea users and 5.8% for insulin 
users, respectively (91). In a longitudinal study of more 
than 8,000 patients with T2DM followed for a median 
of 3 years, Libby et al. showed that those treated with 
metformin had a lower incidence of total cancer than those 
treated with sulphonylureas or insulin, independent of 
age, sex, BMI, hemoglobin A1c, smoking and use of other 
medications (92). In a study including 610 HCC patients, 
618 cirrhotic patients and 1,696 controls, Donadon 
et al. showed that metformin use was associated with a 
significant HCC risk reduction compared with the use of 
sulphonylureas or insulin, in diabetic HCC patients vs. 
control subjects and vs. cirrhotic patients (93). In a hospital-
based study including 420 HCC patients and 1,104 controls, 
Hassan et al. reported that use of sulfonylureas or insulin 
conferred the highest HCC risk, whereas use of metformin 
or glitazones was associated with a 70% risk reduction in 
HCC in patients with T2DM (94). Similarly, in a large 
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Taiwanese population-based study enrolling 19,349 patients 
with newly diagnosed T2DM and 77,396 non-diabetic 
controls, Lai et al. showed that patients with T2DM had 
a two-fold higher incidence of HCC than those without 
T2DM, and that this incidence was significantly lower in 
patients treated with either metformin or glitazones than in 
those treated with other hypoglycemic agents (95). Some 
recent meta-analyses confirmed these findings. In a meta-
analysis of 5 case-control studies, three cohort studies and 
two randomized controlled trials with a total of 22,650 
HCC cases in 334,307 patients with T2DM, Singh et al. 
documented that patients treated with metformin had a 
nearly 50% risk reduction in HCC incidence compared 
with those treated with sulphonylureas, glitazones or 
insulin (96). More recently, in a network meta-analysis of 13 
randomized controlled trials, cohort studies or case-control 
studies enrolling approximately 480,000 T2DM patients 
with more than 240,000 HCC cases, Zhou et al. showed 
that metformin use was associated with decreased HCC 
risk, whereas insulin use was associated with a higher risk of 
this cancer (97). 
That said, it is also important to underline that other 
observational studies produced conflicting results. In a 
retrospective cohort study of nearly 96,000 individuals with 
T2DM who began to take metformin or other oral glucose-
lowering agents within 12 months of the diagnosis, Tsilidis 
et al. showed that the users of sulphonylureas or metformin 
had similar incidence rates of total cancer over 5 years of 
follow-up (98). Similar results were also found when the 
analysis was restricted to incidence rates of different types 
of cancer, such as HCC, colorectal, prostate, lung and 
breast cancers (98). Interestingly, in a post-hoc analysis of 
the ADOPT (A Diabetes Outcome Progression Trial) and 
the RECORD (Rosiglitazone Evaluated for Cardiovascular 
Outcomes and Regulation of Glycaemia in Diabetes) trials, 
Home et al. showed that the cancer incidence rates did 
not allow to support the evidence that use of metformin 
conferred a particular protection against cancer risk 
compared to rosiglitazone (99). In addition, other studies 
did not support the conclusion that metformin may 
reduce the rates of cancer incidence among patients with 
established T2DM (100-102). 
Collectively, there is still uncertainty about whether 
hypoglycemic drugs used for diabetes treatment may 
either increase or decrease the risk of incident HCC, 
or even influence cancer prognosis. Most observational 
studies suggest that metformin use might have any chemo-
preventive effects against HCC, and a biologically plausible 
mechanism also exists (this drug activates AMP-activated 
protein kinase (AMPK) and inhibits the PI3K/AKT/mTOR 
signaling pathway that is important in regulating the cell 
cycle) (1,14,96). In contrast, it is uncertain if the observed 
insulin-related increase in HCC risk is related to toxicity 
associated with the medication, or if it is simply reflective of 
increased HCC risk in patients with more severe diabetes. 
Further larger randomized clinical trials are required in 
order to confirm a possible chemo-protective effect of 
metformin on HCC risk, and to find novel metabolic 
approaches to HCC prevention and treatment in individuals 
with T2DM. 
Conclusions
HCC incidence is rapidly increasing worldwide, and this is 
likely linked to the increasing incidence of T2DM, NAFLD 
and metabolic syndrome. There is now robust evidence of 
an association between T2DM and HCC development. 
The pathophysiology underlying development of HCC 
in this context is complex and is likely to involve NAFLD 
(especially NASH with varying amounts of hepatic 
fibrosis), increased hepatic/peripheral insulin resistance 
hyperinsulinemia, increased pro-inflammatory mediators, 
oxidative stress, JNK-1 activation, increased IGF-1 activity, 
altered gut microbiota and immunomodulation. However, 
a greater understanding of the underlying pathophysiology 
might help in the future development of rational, targeted 
treatments for patients with both HCC and T2DM.
In clinical practice, clinicians are increasingly required 
to manage and treat patients with both T2DM and HCC. 
Although there are still important gaps in our knowledge(s), 
the use of metformin may be associated with a lower 
incidence of HCC. To date, studies reporting on the effect 
of glucose-lowering medications other than metformin on 
HCC prognosis are both scant and difficult to interpret, 
owing to the complexity of pharmacotherapy for T2DM, 
and the many sources of bias that this complexity may 
generate. Further research is required to clarify the variables 
that contribute to the complexity of the associations 
between T2DM, hyperglycemia, diabetes treatment and 
HCC risk.
Given that clinicians increasingly encounter patients 
with coexistent T2DM and HCC, it is desirable that the 
next randomized clinical trials of new drug candidates in 
oncology do not exclude people with T2DM in order to 
Mantovani and Targher. Diabetes and HCC risk
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better understand the pathophysiological mechanisms 
linking T2DM and HCC, and to provide new drugs for 
prevention and treatment of HCC in these patients. 
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Table 1 Principal observational studies and meta-analyses that have explored the association between type 2 diabetes and risk of hepatocellular carcinoma (ordered by publication year)
Study Study characteristics Diabetes diagnosis Covariate adjustment considered Main findings
Adami  HO e t  a l .  Cance r  Causes  Con t ro l 
1991;2:307-14
Hospital-based cohort: 51,008 patients with DM. Mean follow-up: 9 years Hospital discharge diagnosis None DM was associated with increased risk of incident HCC
Adami HO et al. J Natl Cancer Inst 1996;88:1472-7 Hospital-based cohort: 153,852 patients with DM. Follow-up: from 1 to 24 years Hospital discharge diagnosis None DM was associated with increased risk of incident HCC
La Vecchia et al. Int J Cancer 1997;73:204-7 Case-control study: 428 HCC cases, 59 with gallbladder and bile duct cancers, and 1,502 control 
subjects from hospital
Self-reported Age, sex, area of residence, education level, alcohol intake, BMI, 
smoking, history of chronic hepatitis and cirrhosis, family history of liver 
cancer
DM was associated with increased risk of incident HCC
Huo TI  et  a l .  Eur  J  Gastroentero l  Hepatol 
2003;15:1203-8
Prospective study: 239 HCC patients (16.3% of whom had DM). Mean follow-up: 2.6 years Fasting glucose ≥126 mg/dL or 2-hour 
post-load glucose ≥200 mg/dL, or past 
history
Age, sex, tumor size, anti-HCV-Ab positivity, HBeAg-positivity, cirrhosis, 
alcohol intake, alpha-fetoprotein, albumin, bilirubin
DM did not affect long-term survival in HCV-related HCC, but was a recurrence-
independent prognostic factor for HBV-related HCC
Coughlin SS et al. Am J Epidemiol 2004;159:1160-7 Population cohort study: 467,922 men and 588,321 women without history of cancer at baseline. 
Mean follow-up: 16 years 
Self-reported BMI DM was associated with increased risk of incident HCC only in men
El-Serag HB et al. Gastroenterology 2004;126:460-8 Prospective study: 73,643 patients with DM and 650,620 patients without DM. Mean follow-up: 5 
years
Self-reported Alcoholic liver disease, viral chronic hepatitis, demographic variables DM was associated with an increased risk of incident HCC. DM carried the highest risk 
among patients with a follow-up longer than 10 years 
Davilla JA et al. Gut 2005;54:533-9 Population based case-control study: 2,061 HCC patients (of whom 43% with DM) and 6,183 non-
cancer controls (of whom 19% with DM)
Electronic register Age, sex, race, HCV, HBV, alcoholic liver disease, and hemochromatosis DM was associated with a nearly three-fold increased risk of HCC
Inoue M et al. Arch Intern Med 2006;166:1871-7 Prospective study: 97,771 Japanese adult individuals followed-up for cancer incidence over 5 years. 
At baseline, 4.7% of them had DM
Self-reported Age, study area, BMI, prior cardiovascular disease, smoking, alcohol 
intake, leisure-time physical activity, green vegetable intake, coffee 
intake
DM was associated with increased risk of total cancer and cancer in specific sites, 
including HCC
El-Serag HB et al. Clin Gastroenterol Hepatol 
2006;4:369-80
Meta-analysis: a total of 26 studies (of whom 13 case-control studies and 13 cohort studies), 
inclusive of approximately 3 million of individuals
Self-reported Alcohol intake, chronic viral hepatitis, diet, BMI Among 13 cohort studies, DM was associated with an increased risk of HCC
Kawamura Y et al.  J Gastroenterol Hepatol 
2008;23:1739-46
Prospective study: 40 consecutive HCC patients (with HCC associated with non-B, non-C hepatitis), 
and later underwent surgical resection or radiofrequency ablation. Prevalence of DM was 45%. Mean 
follow-up: 5 years
Fasting glucose ≥126 mg/dL or past history Age, sex, dyslipidemia, smoking, alcohol intake, history of blood 
transfusion, state of liver disease (chronic hepatitis or cirrhosis), AST, 
albumin, bilirubin, alpha-fetoprotein, pro-thrombin time, tumor size, 
multiplicity, hyper-vascularity and portal vein invasion of HCC
DM was a significant predictor of tumor recurrence after potentially curative therapy for 
HCC 
Donadon  V  e t  a l .  Wor ld  J  Gas t roen te ro l 
2009;15:2506-11 
Case-control study: 465 HCC patients, 618 with cirrhosis and 490 control subjects. The prevalence 
of DM was 31.2% in HCC, 23.3% in cirrhotic patients and 12.7% in control group 
Self-reported Age, sex, BMI, alcohol abuse, HBV and HCV DM was an independent risk factor for HCC. Among male patients with DM, there 
was a positive association of HCC with insulin/sulphonylurea treatment and an inverse 
association with metformin 
Hassan MM et al. Cancer 2010;116:1938-46 Hospital-based case-control study: 420 patients with HCC and 1,104 healthy controls. The 
prevalence of DM was 33.3% in patients with HCC and 10.4% in controls 
Self-reported Age, sex, race, educational level, smoking, alcohol intake, HCV, HBV, 
family history of cancer
DM increased the risk of HCC. Treatments with sulfonylureas or insulin were 
associated with higher HCC risk, whereas treatments with metformin or glitazones 
were associated with lower HCC risk 
Hense HW et al. Diabetol Metab Syndr 2011;3:15 Community-based study: 26,742 DM patients, who were 40 to 79 years old, resided in the Muenster 
district. Mean follow-up: 3.3 years
Self-reported Sex, diabetes duration, BMI, insulin treatment Risk of any incident cancer in DM was increased, in particular for HCC. Insulin therapy 
was related to higher cancer risk, while metformin was not
Johnson et al. Diabetologia 2011;54:2263-71 Population-based retrospective cohort study: 185,100 individuals with DM and 185,100 without DM, 
matched by sex and age. Mean follow-up: 10 years
Electronic register Age, sex, socio-economic status, number of physician visits, year of 
diagnosis
DM was associated with increased risk of selected cancers, including HCC
Li Q et al. Int J Canc 2012;131:1197-202 Hospital-based case-control study: 1,105 patients with HBV-related HCC and 5,170 patients with 
chronic HBV. The whole prevalence of DM was 6.7%
Fasting glucose ≥126 mg/dL or past history Age, family history of HCC, city of residence, HBV-Ag and cirrhosis DM was associated with increased risk of HCC, only in women
Wang C et al. Int J Cancer 2012;130:1639-48 Meta-analysis: a total of 25 cohort studies, enrolling 1,283,112 persons. Mean follow-up: 8.8 years Self-report, medical records Geographic location, alcohol intake, history of cirrhosis, or HBV and 
HCV infections 
DM was associated with increased risk of incident HCC and higher HCC mortality. 
Longer diabetes duration and use of sulphonylureas or insulin were associated with 
increased risk of HCC. Metformin treatment was protective
Wa n g  P  e t  a l .  D i a b e t e s  M e t a b  R e s  R e v 
2012;28:109-22
Meta-analysis: 17 case-control studies (a total of nearly 6,000 HCC cases and 74,000 controls) and 
32 cohort studies (a total of nearly 6,500,000 individuals) 
Self-report, medical records BMI, prior hepatitis, cirrhosis, alcohol intake, smoking, treatment, 
duration of diabetes
The combined risk estimate of all studies showed a significant increased risk of 
HCC among DM individuals. In addition, meta-analysis of 7 cohort studies found a 
significant increased risk of HCC mortality for individuals with DM compared to those 
without 
Lai SW et al. Am J Gastroenterol 2012;107:46-52 Population-based cohort study: 19,349 newly diagnosed DM patients and 77,396 control subjects 
without DM. Mean follow-up: 5 years 
Electronic register Age, sex, cirrhosis, alcoholic liver damage, viral hepatitis DM was associated with increased risk of incident HCC. Use of metformin or 
glitazones was associated with reduced HCC risk 
Schlesinger S et al. Ann Oncol 2013;24:2449-55 Community-based cohort study: 363,426 participants, after excluding those with cancer at baseline. 
Mean follow-up: 8.5 years
Self-reported Age, sex, center, education level, smoking, alcohol intake, BMI, waist-
to-height ratio
DM was independently associated with higher risk of incident HCC and biliary tract 
cancer. HCC risk was higher in those treated with insulin. Results were similar in HCV/
HBV-negative individuals
Zheng Z et al. PLoS One 2013;8:e84776 Hospital-based retrospective case-control study: 1,568 participants of whom 716 patients were 
diagnosed with benign liver diseases, and 852 patients were diagnosed with HCC. The prevalence of 
DM was 7.6%
Fasting glucose ≥126 mg/dL or 2-hour post-
load glucose ≥200 mg/dL, HbA1c≥6.5% 
Age, sex, HBV and HCV infections, cirrhosis, gallstone disease, 
cholinesterase, alkaline phosphatase
DM was associated with increased risk of HCC. However, there was significant 
interaction between DM and HBV on HCC occurrence 
Koh WP et al. Br J Cancer 2013;108:1182-8 Community-based cohort study: 63,257 middle-aged and older individuals. The prevalence of DM 
was 8.6%. Mean follow-up: 14 years
Self-reported Age, sex, BMI, recruitment year, education level, smoking, alcohol 
intake, consumption of coffee and tea
DM was associated with an increased risk of incident non-viral HCC
M i e l e  L  e t  a l .  G a s t r o e n t e r o l  R e s  P r a c t 
2015;2015:570356
Hospital-based case-control study: 224 HCC patients and 389 controls. The prevalence of DM was 
19.7%
Self-reported Age, sex, smoking, alcohol intake DM was associated with increased risk of HCC. Treatment with any glucose-lowering 
drugs was not associated with increased HCC risk 
Dyal HK et al. Dig Dis Sci 2016;61:636-45 Meta-analysis: 9 studies (7 cohorts and 2 case-controls) with a total of nearly 10,000 adults with 
chronic HCV. The prevalence of DM was 8%
Self-reported Age, sex, BMI, hypertension, smoking, alcohol intake, liver enzymes, 
albumin, lipids, platelet count, cirrhosis, HCV treatment, HCV genotype, 
hepatic steatosis
DM was associated with increased risk of HCC 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DM, diabetes mellitus; GGT, gamma-glutamyltransferase; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma. 
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